IRIS
PISTELLI, MIRCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.801
EU - Europa 711
AS - Asia 643
SA - Sud America 115
AF - Africa 64
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 3.339
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.777
SG - Singapore 213
IT - Italia 171
CN - Cina 132
VN - Vietnam 129
RU - Federazione Russa 108
BR - Brasile 88
SE - Svezia 77
IE - Irlanda 71
DE - Germania 66
UA - Ucraina 60
HK - Hong Kong 45
CI - Costa d'Avorio 43
GB - Regno Unito 41
FR - Francia 40
BD - Bangladesh 33
FI - Finlandia 26
TR - Turchia 24
IN - India 21
CA - Canada 14
DK - Danimarca 14
PL - Polonia 12
KR - Corea 11
AR - Argentina 10
JP - Giappone 10
MX - Messico 9
MA - Marocco 7
ZA - Sudafrica 7
CO - Colombia 5
ES - Italia 5
BE - Belgio 4
CL - Cile 4
IQ - Iraq 4
KE - Kenya 4
NL - Olanda 4
PK - Pakistan 4
AT - Austria 3
AU - Australia 3
EC - Ecuador 3
JO - Giordania 3
AL - Albania 2
CH - Svizzera 2
EU - Europa 2
LB - Libano 2
UZ - Uzbekistan 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
BH - Bahrain 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
ID - Indonesia 1
LT - Lituania 1
MD - Moldavia 1
MM - Myanmar 1
NI - Nicaragua 1
NP - Nepal 1
OM - Oman 1
PH - Filippine 1
PS - Palestinian Territory 1
PY - Paraguay 1
QA - Qatar 1
RO - Romania 1
SR - Suriname 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
UY - Uruguay 1
Totale 3.339
Salva come PNG Salva come JPEG
Città #
Ashburn 309
Chandler 170
Singapore 129
Dallas 121
San Jose 111
Jacksonville 89
Fairfield 80
Dublin 70
New York 68
Boardman 56
Des Moines 55
Houston 44
Abidjan 43
Hong Kong 42
Woodbridge 40
Ho Chi Minh City 39
Seattle 39
Wilmington 38
Beijing 36
Hanoi 32
Los Angeles 31
The Dalles 30
Cambridge 27
Lawrence 22
Munich 22
Princeton 22
Ann Arbor 21
Rome 21
Moscow 20
San Mateo 20
Lauterbourg 17
Centro 15
Chicago 13
Turku 13
Buffalo 12
London 12
San Diego 12
São Paulo 12
Orem 11
Milan 10
Santa Clara 10
Turin 10
Warsaw 10
Washington 10
Montreal 8
Porto 8
Council Bluffs 7
Da Nang 7
Hefei 7
Stockholm 7
Tokyo 7
Boston 6
Cagliari 6
Frankfurt am Main 6
Haiphong 6
Helsinki 6
Phoenix 6
Ancona 5
Brooklyn 5
Cantu 5
Chennai 5
Chiaravalle 5
Denver 5
Falls Church 5
Guangzhou 5
Mexico City 5
Pune 5
Ankara 4
Brasília 4
Brussels 4
Johannesburg 4
New Delhi 4
Nonantola 4
Poplar 4
Prescot 4
Rio de Janeiro 4
Amman 3
Atlanta 3
Birmingham 3
Biên Hòa 3
Bắc Ninh 3
Campinas 3
Columbus 3
Falconara Marittima 3
Hải Dương 3
Kilburn 3
Manchester 3
Miano 3
Mumbai 3
Nairobi 3
Salt Lake City 3
San Francisco 3
Shenzhen 3
Thái Nguyên 3
Wuhan 3
Yiwu 3
Arcene 2
Bogotá 2
Calgary 2
Caserta 2
Totale 2.255
Salva come PNG Salva come JPEG
Nome #
Role of DCE-MR in predicting breast cancer subtypes. 186
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients 171
Long‑responders to anti‑HER2 therapies: A case report and review of the literature 171
Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO) 169
Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. 166
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients 165
Role of DCE-MR imaging of the breast in predicting breast cancer subtypes: where are we going? 162
The impact of lifestyle interventions in high‐risk early breast cancer patients: A modeling approach from a single institution experience 157
Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review 148
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 146
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. 139
Paclitaxel and Bevacizumab in First Line-Treatment Patients with HER-2 Negative Advanced Breast Cancer: Who could Benefit? 137
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 135
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 134
A Mixed-apprOach program To help women wIth breast cancer stay actiVE (MOTIVE program): A pilot-controlled study 134
Expectations and psychological issues before genetic counseling: analysis of distress determinant factors 133
Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report 130
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis 125
Comparison Between Alendronate and Denosumab in Preventing Bone Loss and Lowering Fracture Risk Related to Adjuvant Endocrine Therapy for Breast Cancer: Real-World Data From a Third-Level Center Experience 123
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 123
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012–2035) 121
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 113
Espressione di p-mTOR e del recettore degli androgeni nei tumori mammari triplo negativi: significato clinico e potenziali prospettive terapeutiche 101
Adjuvant Systemic Therapy in DCIS 100
Totale 3.389
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.630
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.630
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202117 0 0 0 0 0 0 0 0 0 0 0 17
2021/2022184 12 28 4 1 2 29 11 9 17 22 17 32
2022/2023455 31 58 30 49 27 99 0 15 97 2 24 23
2023/2024242 46 3 16 17 33 70 4 16 0 3 0 34
2024/2025415 65 45 11 9 24 12 35 10 74 22 55 53
2025/20261.504 120 94 149 167 178 109 227 126 107 106 69 52
Totale 3.389